Lecture series on the doctoring of madness and the creation of psychopharmacology, held at the Unversity Hospital of Psychiatry, Zurich 2008.

1. The Creation of
Psychopharmacology III
David Healy, Harvard University Press, 2002
Felix Hasler HRC
Klinische Forschung Zürich

2. Von den Neuroleptika zu den Antipsychotica
Risperidon (Risperdal®)
1993
Pipamperone (Dipiperon®)

3. Von den Neuroleptika zu den Antipsychotica
Lundbeck: Sertindol (Serdolect® 1996)
Komplikation: Verlängerung des QT-Intervalls

4. Exkurs Herzphysiologie

5. Erstes EKG (1903)

6. Sertindol (Serdolect® 1996)
Komplikation: Verlängerung des QT-Intervalls

7. Rezeptorbindungs-Profil Sertindol
(Seroquel)

8. ECDEU: Empirische Wissenschaft
Max Fink Nathan Kline Leo Hollister

9. Positive and negative schizophrenia
Positive symptoms Negative symptoms
„EGO-
DISORDER“
Cognitive symptoms Behavioral symptoms

10. Externe / Interne Stimuli Externe / Interne Stimuli
Filter intakt Filter „gestört“

11. CSTC-Loop and Sensorimotor Gating
Parietal cortex Prim.-sensori.
Temporal cortex Cortex
Hippocampus
C. m.
-Glu
Frontal
Cortex
Striatum Pallidum Extro-
Thalamus
ceptive
& intro-
-DA +DA ceptive
VTA
Stimuli
+5-HT +5-HT +5-HT
RA

12. D2-Besetzung durch Neuroleptika und
klinische Wirksamkeit I
Agid O, Mamo D, Ginovart N, Vitcu I, Wilson AA, Zipursky RB, Kapur S (2007)
Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response - a
double-blind PET study in schizophrenia. Neuropsychopharmacology 32: 1209-15

13. D2-Besetzung durch Neuroleptika und
klinische Wirksamkeit II

14. Fluoxetin (Prozac®)
Klassischer SSRI
(Selektiver Serotonin-Wiederaufnahme-Hemmer)
„Symbol of the 90ies“

15. Figure 2. Mean Standardized Improvement as a Function of Initial Severity and Treatment
Group.
Drug improvement is portrayed as red triangles around their solid red regression line and placebo
improvement as blue circles around their dashed blue regression line; the green shaded area indicates
the point at which comparisons of drug versus placebo reach the NICE clinical
significance criterion of d ¼ 0.50. Plotted values are sized according to their weight in analyses.
Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug Administration
Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, et al., PLoS Medicine Vol. 5, No. 2, e45 doi:10.1371/journal.pmed.0050045

16. Figure 3. Mean Standardized Improvement as a Function of Initial Severity and Treatment
Group, Including Only Trials Whose Samples Had High Initial Severity
Drug improvement is portrayed as red triangles around their solid red regression line and placebo
improvement as blue circles around their dashed blue regression line; the green shaded area
indicates the point at which comparisons of drug versus placebo reach the NICE clinical significance
criterion of d ¼ 0.50. Plotted values are sized according to their weight in analyses.
doi:10.1371/journal.pmed.0050045.g003

17. Neue Allianzen

18. „Management of behaviour“